The effects of notoginsenoside R1 on the intestinal absorption of geniposide by the everted rat gut sac model

Comparative pharmacokinetics of catalpol and acteoside in normal and chronic kidney disease rats after oral administration of Rehmannia glutinosa extract

“…Additionally, the metabolism enzymes may also be found in other organs such as the kidney and gastrointestinal tract (Gardiner and Begg 2006;Smith et al, 2012). The intestinal absorption of some iridoid glycosides, like geniposide, catalpol and loganin, is enhanced by the inhibition of the intestinal P-gp activity (Chula et al, 2012;Feng et al, 2013;Li et al, 2008). Cytochrome P450 activity within the gut might have a significant effect on the bioavailability of orally administered medicines.…”

“…As the best-studied ATP-binding cassette transporter, P-glycoprotein (P-gp) can expel various drugs from cells, resulting in multidrug resistance, and is likely to play a critical role in the uptake and absorption of substrate drugs (Dreisbach 2009;Naud et al, 2012). The intestinal absorption of some iridoid glycosides, like geniposide, catalpol and loganin, is enhanced by the inhibition of the intestinal P-gp activity (Chula et al, 2012;Feng et al, 2013;Li et al, 2008). Therefore, iridoids glycoside might be a substrate for intestinal P-gp and the decrease in intestinal P-gp could explain the increased bioavailability of catalpol in CKD rats (Kozlowska-Rup et al, 2014).…”

Validated LC‐MS method for simultaneous quantitation of catalpol and harpagide in rat plasma: application to a comparative pharmacokinetic study in normal and diabetic rats after oral administration of Zeng‐Ye‐Decoction

“…Chula et al . () have reported that the intestinal absorption of geniposide, a characteristic iridoids glycoside, is enhanced with the inhibition of the intestinal P‐gp activity and geniposide is probably a substrate of the intestinal P‐gp. As for the iridoids glycosides, the two analytes might be the substrates of multidrug transporter P‐gp in the intestine.…”

“…It has also been widely accepted that the intestinal P-gp can be an active secretion system or an absorption barrier by transporting some drugs from the intestinal cells into the lumen. Chula et al (2012) have reported that the intestinal absorption of geniposide, a characteristic iridoids glycoside, is enhanced with the inhibition of the intestinal P-gp activity and geniposide is probably a substrate of the intestinal P-gp. As for the iridoids glycosides, the two analytes might be the substrates of multidrug transporter P-gp in the intestine.…”

Comparative pharmacokinetics of the main compounds of Shanzhuyu extract after oral administration in normal and chronic kidney disease rats

“…It has also been widely accepted that the intestinal P-gp can be an active secretion system or an absorption barrier by transporting some drugs from the intestinal cells into the lumen. The intestinal absorption of some iridoids glycoside, like geniposide, catalpol and loganin is enhanced with the inhibition of the intestinal P-gp activity (Li et al, 2008;Chula et al, 2012;Qosa et al 2014). Thus, iridoids glycoside is probably a substrate of the intestinal P-gp and a decrease in intestinal P-gp could explain the increased bioavailability of drugs in chronic renal disease rats (Krishnamurthy et al, 2014).…”